Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Robust and sustained efficacy in both adult PKD patients up to 30 months post-RP-L301; first pediatric patient results suggest efficacy similar to adult cohort with initial greater than five-point... | May 19, 2023

Related Keywords

California ,United States ,State Of California ,American ,Investigaciones Energ ,Los Angeles ,Enfermedades Raras ,Kaplan Meier ,Medioambientalesy Tecnol ,Jonathan Schwartz ,Rocket Pharmaceuticals Inc ,Schwartz ,Nasdaq ,Meeting Of The American Society Gene ,California Institute For Regenerative Medicine Grant Number ,Rocket Pharmaceuticals ,Pyruvate Kinase Deficiency ,Fanconi Anemia ,Severe Leukocyte Adhesion Deficiency I ,Danon Disease ,Annual Meeting ,American Society ,Cell Therapy ,Chief Gene Therapy Officer ,Danon Phase ,Lentiviral Mediated Gene Therapy ,Severe Pyruvate Kinase Deficiency ,Mediated Gene Therapy ,Biologics License Application ,Pediatric Patients ,Interim Results ,Ongoing Phase ,Leukocyte Adhesion Deficiency I ,Disease Phase ,First Single Dose Intravenous ,Gene Therapy ,Recombinant Adeno Associated Virus ,Kinase Deficiency ,Centro De Investigaciones Energ ,Centro De Investigaci ,Red De Enfermedades Raras ,Instituto De Investigaci ,Sanitaria De La Fundaci ,California Institute ,Regenerative Medicine ,Grant Number ,Arrhythmogenic Cardiomyopathy ,Nc Stock Exchange ,News ,Information ,Press Release ,Obust ,End ,Sustained ,Efficacy ,N ,Moth ,Adult ,Kd ,Patients ,P ,O , 0 ,Months ,First ,Pediatric ,Patient ,Results ,Uggest ,Similar ,Cohort ,Ith ,Nitial ,Greater ,Han Rckt Us77313f1066 ,